市场概况

The Vitreoretinal Surgery Devices Market is anticipated to witness substantial growth, 预计美元增幅 1.49 十亿 2022 兑美元 1.85 十亿 2029. 预计这一增长将由复合年增长率推动 (复合年增长率) 的 3.0% 在预测期内 2023-2029. Vitreoretinal surgery devices play a crucial role in the treatment of various eye diseases, including macular degeneration, retinal detachment, uveitis, vitreous hemorrhage, macular hole, epiretinal membrane, and complications related to diabetic retinopathy. These devices enable surgeons to perform delicate procedures within the vitreous and retina, restoring or preserving vision for patients.

The increasing incidence of eye disorders, particularly among the elderly population, is a key driver for the growth of the vitreoretinal surgery devices market. With the aging population, the prevalence of age-related eye diseases such as macular degeneration and diabetic retinopathy is expected to rise, creating a greater demand for effective treatment options.

此外, the rising geriatric population is expected to contribute to the burden of eye diseases, further driving the market growth. As the elderly population continues to grow, there is a greater need for advanced vitreoretinal surgery devices to address the specific challenges and complexities associated with age-related eye conditions.

In response to the growing demand, companies operating in the vitreoretinal surgery devices market are actively launching new products and forming collaborations to expand their market presence. These initiatives aim to enhance the surgical outcomes, improve patient experience, and address the evolving needs of ophthalmic surgeons.

市场细分

市场根据多种因素进行细分, including product type, surgery type, 和地理.

Segmentation by Product Type
Perfluoro Carbon Liquids
Endoillumination Instruments
Vitreoretinal Prefilled Silicone Oil Syringes
Virectomy System
其他的

Segmentation by Surgery Type
Anterior Vitreoretinal Surgery
Posterior Vitreoretinal Surgery

按地理位置细分
北美 – 美国, 加拿大, 墨西哥
欧洲 – 英国, 德国, 法国, 意大利, 西班牙, 和欧洲其他地区
亚太 – 中国, 日本, 印度, 澳大利亚, 韩国, 以及亚太地区其他地区
拉美 – 巴西, 阿根廷, 和拉丁美洲其他地区
中东和非洲 – GCC, 南非, 以及中东和非洲其他地区

Pars plana vitrectomy (PPV) is a widely used technique in vitreoretinal surgery, providing access to the posterior segment of the eye for treating conditions like retinal detachments, vitreous hemorrhage, endophthalmitis, and macular holes. This closed, controlled procedure ensures precise and effective treatment. The demand for posterior vitrectomy, which addresses diseases of the retina and vitreous, is driven by the high prevalence of conditions like diabetic retinopathy and posterior vitreous detachment. Consequently, the growth of the posterior vitreoretinal surgery segment is expected to be influenced significantly by these factors, resulting in a substantial market share throughout the forecast period.

North America is expected to have a significant share in the vitreoretinal surgery devices market, driven by the region’s high prevalence of eye diseases and increasing geriatric population. The rising elderly population contributes to market growth, as vitreoretinal surgeries are commonly recommended for age-related eye disorders. Companies in this market are actively launching products and forming partnerships to expand their presence. The high prevalence of eye diseases, along with the growing geriatric population, drives market growth. The posterior vitreoretinal surgery segment holds a substantial market share, and North America is a prominent region in terms of market size. Ongoing advancements and collaborations further contribute to market expansion.

竞争格局

The Vitreoretinal Surgery Devices Market is moderately competitive, with global and regional companies. The competitive landscape involves analyzing companies based on factors like product launches, 收购, collaborations, and agreements. Notable companies include Alcon AG, 鲍什 & 伦姆公司, D.O.R.C. 荷兰眼科研究中心 (国际的) B.V., Geuder AG, MedOne Surgical, 公司, OCULUS Optikgerate GmbH, 除其他外.

最新行业发展

Moria, a French company, successfully acquired AlchimiaSRL, an Italian company, in July 2022. AlchimiaSRL specializes in manufacturing devices for ophthalmic surgery and human tissue banking. This strategic acquisition will enhance Moria’s existing range of products for vitreoretinal surgery and keratoplasty.

In May 2022, D.O.R.C. 荷兰眼科研究中心 (国际的) obtained 510(k) premarket approval from the United States Food and Drug Administration (FDA) for their EVA NEXUS Ophthalmic Surgical System. This advanced system is designed for precise subretinal microinjection of gases or aqueous fluids in vitreoretinal ophthalmic surgery.

为什么选择这份报告

Gain a reliable outlook of the global vitreoretinal surgery devices market forecasts from 2023 到 2029 跨场景.
确定投资的增长领域.
通过公司简介和市场数据领先于竞争对手.
Excel 格式的跨场景分析易用性的市场预估.
三个月的战略咨询和研究支持.
为单用户许可证提供打印验证.